A Retrospective Chart Review of BOTOX® and Xeomin® for the Management of Cervical Dystonia and Blepharospasm
Completed
- Conditions
- Cervical DystoniaBlepharospasm
- Interventions
- Other: No Intervention
- Registration Number
- NCT02245958
- Lead Sponsor
- Allergan
- Brief Summary
This study is a retrospective chart review to evaluate the doses of botulinum Type A toxins BOTOX® (onabotulinumtoxinA) and Xeomin® (incobotulinumtoxinA) used for the treatment of Cervical Dystonia and Blepharospasm in clinical practice.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 44
Inclusion Criteria
- Confirmed primary diagnosis of idiopathic cervical dystonia or blepharospasm for at least 2 years
- Treatment with Xeomin® and BOTOX® for at least 2 years each.
Exclusion Criteria
- Having a neuromuscular junction transmission disorder or taking any medications that could affect neuromuscular junction transmission
- Previous surgical procedure involving bone or muscle for the management of cervical dystonia or blepharospasm.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description BOTOX® No Intervention Retrospective chart review of doses of BOTOX® (onabotulinumtoxinA) used as standard of care in clinical practice. No treatment (intervention) was administered. Xeomin® No Intervention Retrospective chart review of doses of Xeomin® (incobotulinumtoxinA) used as standard of care in clinical practice. No treatment (intervention) was administered.
- Primary Outcome Measures
Name Time Method Dose of Botulinum Toxin Used to Treat Cervical Dystonia 4 Years Dose of Botulinum Toxin Used to Treat Blepharospasm 4 Years
- Secondary Outcome Measures
Name Time Method Botulinum Toxin Inter-injection Intervals 4 Years Number of Participants with Adverse Events 4 Years Annual Botulinum Toxin Dose per Patient 4 Years